Zykadia Approved For Late-Stage Lung Cancer

The FDA granted accelerated approval to Zykadia (ceritinib) to treat patients with a certain type of late-stage (metastatic) non-small cell lung cancer (NSCLC). The drug was approved 4 months ahead of its review completion goal date as part of the FDA's accelerated approval program.